DSHEA Compliance Isn't Enough for Canada: How to Build a Dual-Market Supplement Testing Program

A dietary supplement company headquartered in Illinois can legally sell its turmeric extract in the US the day its 21 CFR Part 111 GMP documentation is in order. Selling that same product in Canada requires a product license — an NPN — which means Health Canada reviewers will scrutinize every piece of testing data behind it before a single unit crosses the border.

That asymmetry catches a lot of Midwest brands off guard. The two regulatory frameworks — DSHEA in the US, the Natural Health Products Regulations (NHPR) in Canada — share language and intent. Both require manufacturers to establish identity, purity, and potency. But the evidentiary standards, documentation formats, and acceptable testing methods diverge enough that a testing package assembled for one rarely transfers cleanly to the other.

If you’re already selling in the US and eyeing the Canadian market — or managing ingredient sourcing for products that ship north and south of the border — here’s where the gaps typically appear and how to build a testing program that satisfies both regulators from the start.

How the Two Frameworks Actually Differ on Pre-Market Evidence

DSHEA, passed in 1994, operates on a notification model. Manufacturers are responsible for safety and compliance under 21 CFR Part 111, but there’s no pre-market approval process for most dietary supplements. The FDA can act after a product reaches market, but a brand doesn’t need to prove anything to a reviewer before launch.

The NHPR flips that burden entirely. In force since January 1, 2004 (SOR/2003-196), it requires manufacturers to obtain a Natural Product Number before commercializing in Canada. That means submitting a product license application containing evidence of safety, efficacy, and quality — including raw material testing data that satisfies Health Canada’s guidance on NHP quality. Every ingredient. Every lot specification. Documented and submitted upfront.

That pre-market review requirement is what makes dual-market compliance so documentation-intensive. Under DSHEA, a brand’s internal batch records and supplier CoAs may never be reviewed by anyone outside the company unless there’s an FDA inspection. Under the NHPR, those same documents — or their Canadian equivalents — go to Health Canada before the NPN is granted.

The practical consequence: analytical testing labs working with dual-market brands need to produce CoAs that can function in both contexts. That means explicit method references, standard citations, and limit comparisons that a Health Canada reviewer can evaluate without requesting additional information.

Where Raw Material Testing Requirements Diverge

The day-to-day differences between the two regimes come down to four areas: identity, heavy metals, microbiology, and potency documentation.

Identity Testing

Both 21 CFR 111.75(a)(1) and Health Canada’s NHP quality guidance require identity confirmation for incoming raw materials. But the NHPR guidance is notably more prescriptive about acceptable methods for botanical ingredients. For herbs like ashwagandha, echinacea, and elderberry, Health Canada often expects HPTLC data with comparative reference standards — not just organoleptic examination or a supplier-issued CoA. DNA barcoding is gaining acceptance as a supplementary tool, particularly for powdered botanicals where morphological assessment isn’t possible, but it hasn’t displaced chromatographic methods for regulatory submissions in Canada.

Under 21 CFR 111.75(a)(1), manufacturers must confirm the identity of 100% of incoming dietary ingredient lots, but the method is less prescribed. Many US brands satisfy this with a combination of supplier CoA review and basic in-house testing. That approach is unlikely to satisfy a Health Canada reviewer for a product license application.

Heavy Metals

USP <232> sets elemental impurity limits for dietary supplement products: 5 µg/day for lead (oral), 15 µg/day for inorganic arsenic, 5 µg/day for cadmium, and 30 µg/day for mercury, among others. These are per-dose limits, not per-gram limits — the calculation depends on ingredient loading in the finished formula, which means analytical testing labs need to know the intended daily dose before they can issue a compliant CoA.

Health Canada takes a similar approach but references its own Guidance Document on the Quality of Natural Health Products. The acceptable daily intake limits are largely aligned with USP <232>, but the citation matters. An ICP-MS test report that says only “meets USP <232> limits” won’t automatically satisfy a Health Canada reviewer. The CoA needs to state actual measured values and show how they compare to the NHPR’s applicable thresholds — an extra column in a results table, essentially, but one that brands without dual-market experience routinely omit.

Microbiology

USP <61> (microbial enumeration) and USP <62> (specified organisms) are the US standards of record. Health Canada’s NHP quality guidance references substantially similar microbial categories and acceptance criteria — total aerobic count, total combined yeasts and molds, and absence of Salmonella, E. coli, and Staphylococcus aureus in specified sample quantities. For most botanical raw materials, a single microbiology panel run to USP <61>/<62> specifications will satisfy both regulators, provided the CoA includes the test method reference and is generated by an accredited laboratory.

The exception: some botanical raw materials destined for the Canadian market require additional pathogen testing that isn’t always included in a standard US panel. Pseudomonas aeruginosa screens, for example, are relevant for certain topical or semi-solid ingredient categories. Worth reviewing against the specific product classification before submitting an NPN application.

Potency and Marker Compound Data

This is where the divergence is sharpest. Many US supplement brands maintain potency specifications for their raw materials without independent HPLC documentation of specific marker compounds. For something like a green tea extract standardized to 45% EGCG, the supplier CoA claim may be accepted at face value if identity testing confirms the material is genuinely green tea.

Health Canada expects quantitative potency data — HPLC assay results, not just a standardized percentage claim from the supplier — for botanicals where a marker compound drives the product’s claimed health benefit. If you’re building an NPN application for a product tied to a specific constituent level (piperine in black pepper, curcuminoids in turmeric, ginsenosides in ginseng), you’ll need HPLC data that independently verifies those levels. Supplier CoAs are not sufficient for the product license application on their own.

Building a Testing Protocol That Covers Both Markets

The most practical approach is to design your raw material specification sheets and incoming testing protocol around the more demanding of the two standards — which usually means starting with Health Canada’s requirements and confirming that USP equivalents are met along the way.

The core testing package for a botanical raw material in a dual-market product typically includes:

1. Botanical identity by HPTLC with reference standard comparison — accepted by both regulators; provides the chromatographic documentation Health Canada requires and satisfies 21 CFR 111 identity requirements simultaneously
2. ICP-MS heavy metals panel covering all USP <232> elements, with quantitative results compared against both USP <232> limits and Health Canada’s acceptable daily intakes — the format, not the data, is what often needs adjustment
3. Microbial enumeration by USP <61> — total aerobic count, total combined yeasts and molds count
4. Specified organisms screen by USP <62> — Salmonella, E. coli, Staphylococcus aureus at minimum, plus any category-specific pathogens relevant to the Canadian product license
5. Potency/marker compound assay by HPLC for standardized botanicals — non-negotiable for NPN applications where efficacy is tied to a constituent level
6. Moisture and solvent residue testing where applicable — particularly relevant for powdered extracts and spray-dried ingredients

Running this panel through an ISO 17025-accredited analytical testing lab ensures the resulting CoA carries the methodological credibility that Health Canada reviewers look for. Accreditation doesn’t guarantee regulatory acceptance, but it removes a common objection and generally eliminates requests for supplementary method-validation data.

The Documentation Detail That Derails More Applications Than Bad Data

In our experience reviewing dual-market testing packages, the most common problem isn’t analytical failure — it’s incomplete documentation. A brand’s ICP-MS data may show fully compliant heavy metal levels, but if the CoA doesn’t state the measured value alongside the applicable limit from the NHPR guidance document, a Health Canada reviewer can’t confirm compliance without a clarification request. That can add three to six weeks to an NPN application timeline.

The same issue appears with identity testing. HPTLC data may be technically sound, but if the CoA doesn’t name the reference standard used — including lot number, where applicable — the result is essentially unverifiable. Health Canada’s quality guidance is explicit: test methods must be described sufficiently that a reviewer can assess their suitability.

A compliant CoA for dual-market use should include, for each test: the method name and version (e.g., “HPTLC per USP <203>”), the reference standard with lot number, the quantitative result with units, the applicable specification limit with its source citation, and a clear pass/fail determination. That format works for 21 CFR Part 111 internal batch records and NHPR product license submissions without modification. Getting analytical testing labs to generate this format from the beginning of the supplier relationship is far easier than retroactively requesting amended reports.

What This Means for Midwest Brands in Practice

The Midwest has a genuinely useful geographic position for dual-market supplement companies. Chicago is one of the country’s major customs processing hubs, and a significant volume of botanical ingredient imports from South Asia, South America, and China arrive here before distribution to both US manufacturers and Canadian importers. Brands operating their own manufacturing near the Great Lakes corridor are often already shipping to both markets — sometimes without realizing that their compliance infrastructure hasn’t kept pace with their distribution footprint.

The practical starting point is a gap analysis on your current raw material specification sheets and supplier CoA requirements. For each botanical ingredient in a product you sell or plan to sell in Canada, flag which testing elements reference only DSHEA standards and which explicitly address NHPR requirements. That map tells you exactly where your analytical testing labs need to generate supplementary data or update CoA formats — before you’re six months into an NPN application and Health Canada sends a clarification request.

Small adjustments made upfront — a more explicit CoA format, an added HPLC assay, a second standard reference on the heavy metals report — cost a fraction of retroactively sourcing documentation under deadline pressure. And unlike many regulatory preparation tasks, this one translates directly into a stronger supplier qualification program regardless of where you’re selling.

---

Written by Nour Abochama, VP Operations, Qalitex | Quality Consultant, Ayah Labs. Learn more about our team

Ship your sample to our Chicago facility — get a Qalitex CoA in 5–7 days. Contact us

Related from our network

• ISO 17025-Accredited Botanical and Supplement Testing — Qalitex Laboratories performs HPTLC identity, ICP-MS heavy metals, and USP microbiology testing for supplement brands across North America, with CoAs formatted for both DSHEA and international regulatory submissions.